Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
Relevance of anti-Müllerian hormone on in vitro fertilization outcome
1 Department of Obstetrics and Gynecology, Istanbul University School of Medicine, Istanbul (Turkey)
Clin. Exp. Obstet. Gynecol. 2013, 40(1), 66–69;
Published: 10 March 2013
Purpose: The aim of this study was to investigate the relevance of serum and follicular anti-Müllerian hormone (AMH) concentrations on ovarian reserve and clinical pregnancy. Materials and Methods: Thirty patients were prospectively included in this study. Serum AMH levels were quantitatively measured on the follicle aspiration day. Retrieving less than five oocytes was defined as poor response. Eleven days after embryo transfer, beta-human chorionic gonadotropin (β-hCG) level in the blood was measured. Two weeks after the β-hCG test, a clinical pregnancy was confirmed by transvaginal ultrasound (TVUS). Results: There was a statistically significant correlation between serum AMH and number of retrieved oocytes (p = 0.024). There was a correlation between the number of retrieved oocytes and baseline antral follicle count (AFC), between ovarian reserve and baseline follicle-stimulating hormone (FSH), and between ovarian reserve and serum AMH (p < 0.05). Serum AMH cut-off value for the normal ovarian reserve was calculated as 0.37ng/ml (sensitivity 71.43%, specificity 66.67%, positive prediction 83.33%, negative prediction 50%). Conclusion: Increasing use of serum AMH will be of considerable benefit. Consequently, the observed positive correlation between serum AMH and ovarian reserve will require larger sampling to refine the role of AMH.
Follicular anti-Müllerian hormone
In vitro fertilization
Serum anti-Müllerian hormone